Astrazeneca Plc (NYSE:AZN – Get Free Report) has received an average recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and fourteen have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $206.6667.
Several analysts have recently issued reports on the company. HSBC downgraded Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Deutsche Bank Aktiengesellschaft raised shares of Astrazeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, September 15th. CICC Research initiated coverage on shares of Astrazeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 target price on the stock. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Finally, Bank of America reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st.
Read Our Latest Stock Analysis on Astrazeneca
Astrazeneca Trading Down 2.8%
Astrazeneca (NYSE:AZN – Get Free Report) last posted its earnings results on Monday, July 27th. The company reported $2.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. The firm had revenue of $15.38 billion for the quarter, compared to analyst estimates of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.Astrazeneca’s revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.17 EPS. Equities analysts forecast that Astrazeneca will post 9.37 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the business. Mascoma Wealth Management LLC acquired a new position in Astrazeneca in the first quarter valued at $26,000. MV Capital Management Inc. acquired a new stake in Astrazeneca in the 4th quarter worth about $26,000. Roxbury Financial LLC acquired a new stake in Astrazeneca in the 2nd quarter worth about $29,000. Reflection Asset Management purchased a new stake in Astrazeneca in the 4th quarter valued at about $31,000. Finally, Resources Management Corp CT ADV purchased a new stake in Astrazeneca in the 1st quarter valued at about $35,000. 20.35% of the stock is currently owned by institutional investors and hedge funds.
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines. Its principal therapeutic areas include oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases.
The company’s portfolio includes medicines such as Tagrisso, Imfinzi and Lynparza for cancer; Farxiga for cardiovascular, kidney and metabolic conditions; Fasenra for severe asthma; and Symbicort for respiratory disease.
Featured Stories
- Five stocks we like better than Astrazeneca
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.